Effect of GABAB Agonist on Visceral Hyperalgesia in NCCP patientsChinese?

Is Visceral Hyperalgesia the Culprit of Noncardiac Chest Pain in Chinese? Part 2: Effect of GABAB Agonist on Visceral Hyperalgesia in NCCP Patients

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00164801

Enrollment

Registered

2005-09-14

Start date

2004-11-30

Completion date

2007-01-31

Last updated

2008-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Cardiac Chest Pain

Brief summary

The effect of baclofen (GABAB agonist), diltiazem (muscle relaxant) and placebo will be compared in a double-blinded randomized study for the treatment of NCCP. Cerebral cortical, brainstem and spinal evoked potentials before and after treatment will be evaluated. Results of this study will shed lights on pathogenesis and treatment of NCCP in Chinese.We hypothesize that Baclofen alleviates visceral hyperalgesia in NCCP patients by suppressing afferent sensory pathway.

Interventions

DRUGBaclofen, Diltiazem

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Inclusion criteria

* Consecutive patients with monthly angina-like chest pain and negative coronary angiogram or scintigraphy * Age between 18-70 * Gastroesophageal reflux disease * Psychiatric illness * Cerebrovascular accident * Active peptic ulceration * Heart failure or cardiac bradyarrhythmia * Epilepsy * Pregnancy or lactating female * Previous hypersensitivity to muscle relaxant

Design outcomes

Primary

Measure	Time frame
Esophageal sensory and pain thresholds	—

Secondary

Measure	Time frame
Symptom severity of chest pain at the end of treatment	—
Evoked potential responses	—

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026